Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) saw a significant increase of over 6%, currently trading at 10.89 HKD with a transaction volume of 10.4175 million HKD, following the announcement of a new drug clinical trial application for JSKN033 [1] Group 1: Clinical Trial Announcement - Corning Jereh Pharmaceutical-B announced that the clinical trial application for JSKN033, a high-concentration subcutaneous compound formulation combining a HER2 bispecific antibody-drug conjugate (ADC) and a PD-L1 immune checkpoint inhibitor, has been officially accepted by the National Medical Products Administration (NMPA) [1] - The JSKN033-202 trial is an open-label, multicenter, Phase II clinical trial aimed at evaluating the safety, efficacy, and pharmacokinetic/pharmacodynamic characteristics of JSKN033 in combination with platinum-based chemotherapy, with or without Bevacizumab, for first-line treatment of advanced cervical cancer [1] - All patients in the trial will receive treatment with JSKN033 in combination with either Cisplatin or Carboplatin, with the choice of platinum drug and the decision to use Bevacizumab being determined by the researchers based on individual patient circumstances [1]
康宁杰瑞制药-B涨超6% 近日SKN033的一项II期临床试验IND申请获受理